EXCLUSIVE LICENSE AND OPTION AGREEMENT by and between FibroGen, Inc. and HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics) Dated as of June 16, 2021Exclusive License and Option Agreement • August 9th, 2021 • Fibrogen Inc • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into as of June 16, 2021 (the “Effective Date”) by and among HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics), a limited company organized and existing under the laws of Hong Kong, with a registered address at Room 303, Third Floor, St. George’s Building, 2 Ice House Street, Central, Hong Kong (“HFB”), and FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, CA 94158 (“FibroGen”). HFB and FibroGen are referred to herein individually as a “Party” and collectively as the “Parties.”
SIXTH AMENDMENT TO LEASELease • August 9th, 2021 • Fibrogen Inc • Pharmaceutical preparations • Illinois
